Sign up
Pharma Capital

CytoDyn CEO says FDA has offered 'a good path forward' for its HIV drug

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassen tells Proactive Investors the biotech held a productive phone conversation with the FDA in which it won key concessions for its flagship HIV drug leronlimab.

Pourhassen says regulators offered 'a good path forward' for leronlimab, as they recognized the higher dosage of 700mg in a monotherapy trial for leronlimab, an injectable antibody that takes aim at HIV, had a much higher response rate than the 350mg dose used in a combination therapy trial. Pourhassen says the company will now submit a Biologics License Application (BLA) to move the drug forward.

 

View full CYDY profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.